Logo for BerGenBio

BerGenBio Investor Relations Material

Latest events

Logo for BerGenBio

Q4 2023

BerGenBio
Logo for BerGenBio

Q4 2023

14 Feb, 2024
Logo for BerGenBio

Q3 2023

14 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from BerGenBio

Access all reports
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. BerGenBio has also initiated its early stage development programs on epacadostat and devicine.